IL-1β Reporter 293 Cell Line

Description

Interleukin-1 (IL-1) is a crucial pro-inflammatory cytokine consisting of two forms, IL-1α and IL-1β, mainly produced by macrophages and macrophage-like cells but also by endothelial and epithelial cells. Both IL-1 forms utilize IL-1R1 and IL-1R2 receptors, with downstream signaling occurring through IL-1R1 binding, while binding to IL-1R2 does not trigger cellular signaling. IL-1 binding to IL-1R1 recruits the IL-1RAcP to the cell membrane, forming a high-affinity receptor complex, initiating intracellular signal transduction.IL-1α is rarely detected in the circulation during disease states, whereas IL-1β contributes to various autoimmune inflammatory reactions and cellular activities, playing a crucial role in inflammation and host responses to infections. Elevated IL-1β levels are closely associated with atherosclerosis, type 2 diabetes, and various autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and Crohn’s disease. Blocking IL-1β receptors with antagonists can alleviate the severity of autoimmune inflammatory diseases. The synthesis, release, and activity of IL-1β are tightly regulated, with the immune system evolving multiple mechanisms to control IL-1β imbalance, including pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).The IL-1β Reporter 293 Cell Line is a reporter gene cell line constructed based on the IL-1β downstream signaling pathway, utilizing Luciferase as a reporter gene. When IL-1β binds to IL-1R1/IL-1RAcP, it activates the downstream signaling pathway, leading to the expression of luciferase. Luciferase readings reflect the activation effect of the signaling pathway, making it useful for evaluating the in vitro effects of IL-1β-related drugs.